Abpro Holdings, Inc. (ABP)
NASDAQ: ABP · Real-Time Price · USD
0.5810
-0.0164 (-2.75%)
At close: Feb 18, 2026, 4:00 PM EST
0.5836
+0.0026 (0.45%)
Pre-market: Feb 19, 2026, 5:50 AM EST
Abpro Holdings Employees
As of December 31, 2024, Abpro Holdings had 15 total employees, including 6 full-time and 9 part-time employees. The number of employees decreased by 27 or -64.29% compared to the previous year.
Employees
15
Change
-27
Growth
-64.29%
Revenue / Employee
n/a
Profits / Employee
-$1,469,333
Market Cap
1.58M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 15 | - | - | 6 | 9 |
| Sep 30, 2024 | 16 | - | - | 15 | 1 |
| Jun 30, 2024 | 16 | - | - | 15 | 1 |
Related Stocks
| Company Name | Employees |
|---|---|
| HCW Biologics | 36 |
| Virax Biolabs Group | 19 |
| Cardio Diagnostics Holdings | 15 |
| Azitra | 12 |
| BioRestorative Therapies | 11 |
| Ensysce Biosciences | 8 |
| CNS Pharmaceuticals | 5 |
| Onconetix | 5 |
ABP News
- 4 weeks ago - Abpro's Lead Program ABP-102 Featured in Celltrion Presentation at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 6 weeks ago - Abpro and Celltrion, Inc. Announce U.S. FDA IND Clearance for Lead Multispecific Antibody Cancer Candidate ABP-102 / CT-P72 - GlobeNewsWire
- 2 months ago - Abpro Holdings Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T cell engager ABP-102/CT-P72 for HER2-positive Cancers - GlobeNewsWire
- 2 months ago - Abpro Granted Nasdaq Listing Extension to Pursue Compliance and Strategic Objectives - GlobeNewsWire
- 3 months ago - Abpro and Celltrion to Present Preclinical Data for CT-P72/ABP-102 at SITC 2025, Highlighting a Next-Generation HER2×CD3 T-Cell Engager - GlobeNewsWire
- 3 months ago - Abpro Announces 1-for-30 Reverse Stock Split Effective November 3, 2025 - GlobeNewsWire
- 10 months ago - Abpro and Celltrion Unveil Preclinical Data for ABP-102/CT-P72 at AACR 2025, Showcasing Potential Best-in-Class HER2 x CD3 T-Cell Engager - GlobeNewsWire
- 11 months ago - Abpro Announces Oral Presentation of First Preclinical Data for ABP-102/CT-P72, a Tetravalent Bispecific HER2 x CD3 T-Cell Engager, at AACR Annual Meeting 2025 - GlobeNewsWire